Epidemiological spectrum and diagnosis patterns of hematological malignancies in the republic of moldova

Le résumé fourni par la source

hematol transfus cell ther. 2 0 2 0;4 2(S 1):S35-S78 S39 (moderate risk) and Binet B (moderate risk).However, in consideration of his weight loss and symptomatic extranodal involvement, a chemotherapy protocol with bendamustine and the CD20 antibody rituximab (BR) was initiated.BR treatment was administered every 28 days for up to 6 courses.The patient's symptoms demonstrated marked improvement after two cycles of chemotherapy.After a total of 4 courses, lymphocytosis in the peripheral blood showed complete remission and the involvement that had been visualized on direct chest radiography and CT showed nearly complete remission.After 6 cycles of chemotherapy, the patient was considered in complete remission and follow-up was started.Conclusion: Pulmonary complications and involvement in CLL typically occur after the diagnosis, in the course of the disease, while there are cases who present as pulmonary involvement (broncho-pulmonary infiltrates, hilar and mediastinal lymphadenopathies, pleural effusion, etc.), although much less frequently.Pulmonary involvement must be considered in patients diagnosed with CLL who have symptoms associated with the respiratory system.Particularly in patients diagnosed with broncho-pulmonary lesions based on peripheral blood analysis or lymph node biopsy, CLL-associated involvement should certainly be included in the differential diagnosis when the most common causes are excluded.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.